Pharmacological prevention and treatment of vascular dementia: Approaches and perspectives

Experimental Gerontology

Volumn 47, Issue 11, 2012, Pages 887-891

  Baskys, Andrius ^a   Cheng, Jin xiang ^b,c  

^a Alzheimer's Disease Prevention and Treatment Center   (United States)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acetylsalicylic acid; Antihypertensives; Donepezil; Folic acid; Galantamine; Ginkgo biloba; Huperzine A; Memantine; Rivastigmine; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CITICOLINE; DIHYDROERGOTOXINE MESILATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DONEPEZIL; FOLIC ACID; GALANTAMINE; GINKGO BILOBA EXTRACT; HUPERZINE A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEMANTINE; NICERGOLINE; NIMODIPINE; PLACEBO; RIVASTIGMINE;

ALZHEIMER DISEASE; ALZHEIMER DISEASE FUNCTIONAL ASSESSMENT AND CHANGE SCALE; ALZHEMER DISEASE ASSESSMENT SCALE COGNITIVE; ANOREXIA; ANTIHYPERTENSIVE THERAPY; ANXIETY DISORDER; ARTICLE; BLEEDING; BRAIN DYSFUNCTION; CADASIL; CEREBROVASCULAR ACCIDENT; CLINICAL DEMENTIA RATING SCALE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICIAN INTERVIEW BASED IMPRESSION OF CHANGE WITH CAREGIVER INPUT; CONFUSION; DAILY LIFE ACTIVITY; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DISABILITY ASSESSMENT FOR DEMENTIA SCALE; DISEASE ASSOCIATION; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSLIPIDEMIA; EARLY INTERVENTION; EXECUTIVE INTERVIEW 25 SCALE; GENE; GENE MUTATION; GENETIC POLYMORPHISM; HEADACHE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LEARNING DISORDER; MEMORY DISORDER; MINI MENTAL STATE EXAMINATION; MTHFR GENE; MULTIINFARCT DEMENTIA; NAUSEA; NEUROLOGIC EXAMINATION; NEUROPROTECTION; NEUROPSYCHIATRIC INVENTORY; NOTCH3 GENE; NURSE OBSERVATIONAL SCALE FOR GERIATRIC PATIENT; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; TINNITUS; TRANSIENT ISCHEMIC ATTACK; UNSPECIFIED SIDE EFFECT; VERTIGO; VOMITING;

ALZHEIMER DISEASE; ANTIHYPERTENSIVE AGENTS; ASPIRIN; CHOLINESTERASE INHIBITORS; COGNITION; DEMENTIA, VASCULAR; DISEASE PROGRESSION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; HYPERTENSION; MEMANTINE; STROKE;

GINKGO BILOBA;

EID: 84867698630     PISSN: 05315565     EISSN: 18736815     Source Type: Journal    
DOI: 10.1016/j.exger.2012.07.002     Document Type: Article

References (43)

1. Areosa S.A., Sherriff F., McShane R. Memantine for dementia. Cochrane Database Syst Rev. 2005, 3:CD003154.
2. Auchus A.P., Brashear H.R., Salloway S., Korczyn A.D., De Deyn P.P., Gassmann-Mayer C. Galantamine treatment of vascular dementia: a randomized trial. Neurology 2007, 69(5):448-458.
3. Ballard C., Sauter M., Scheltens P., He Y., Barkhof F., van Straaten E.C., et al. Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. Curr. Med. Res. Opin. 2008, 24(9):2561-2574.
4. Baskys A., Hou A.C. Vascular dementia: pharmacological treatment approaches and perspectives. Clin. Interv. Aging 2007, 2(3):327-335.
5. Birks J., Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst. Rev. 2009, (1):CD003120.
6. Black S., Roman G.C., Geldmacher D.S., Salloway S., Hecker J., Burns A., et al. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003, 34(10):2323-2330.
7. Chang-Quan H., Hui W., Chao-Min W., Zheng-Rong W., Jun-Wen G., Yong-Hong L., et al. The association of antihypertensive medication use with risk of cognitive decline and dementia: a meta-analysis of longitudinal studies. Int. J. Clin. Pract. 2011, 65(12):1295-1305.
8. Coleman B.R., Ratcliffe R.H., Oguntayo S.A., Shi X., Doctor B.P., Gordon R.K., et al. [+]-Huperzine A treatment protects against N-methyl-D-aspartate-induced seizure/status epilepticus in rats. Chem. Biol. Interact. 2008, 175(1-3):387-395.
9. Craig D., Birks J. Galantamine for vascular cognitive impairment. Cochrane Database of Systematic Reviews 2009, John Wiley & Sons, Ltd., Chichester, UK.
10. Dichgans M., Markus H.S., Salloway S., Verkkoniemi A., Moline M., Wang Q., et al. Donepezil in patients with subcortical vascular cognitive impairment: a randomised double-blind trial in CADASIL. Lancet Neurol. 2008, 7(4):310-318.
11. Ehret G.B., Munroe P.B., Rice K.M., Bochud M., Johnson A.D., Chasman D.I., et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 2011, 478(7367):103-109.
12. Gorelick P.B., Scuteri A., Black S.E., Decarli C., Greenberg S.M., Iadecola C., et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke 2011, 42(9):2672-2713.
13. Ihl R., Tribanek M., Bachinskaya N. Efficacy and tolerability of a once daily formulation of Ginkgo biloba extract EGb 761® in Alzheimer's disease and vascular dementia: results from a randomized controlled trial. Pharmacopsychiatry 2012, 45(2):41-46. GOTADAY Study Group.
14. Kavirajan H., Schneider L.S. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol. 2007, 6(9):782-792.
15. Kellermann A.J., Kloft C. Is there a risk of bleeding associated with standardized Ginkgo biloba extract therapy? A systematic review and meta-analysis. Pharmacotherapy 2011, 31(5):490-502.
16. Kirshner H.S. Vascular dementia: a review of recent evidence for prevention and treatment. Curr. Neurol. Neurosci. Rep. 2009, 9(6):437-442.
17. Li J., Wu Hong M., Zhou Rongle L., Liu Guan J., Dong Bi R. Huperzine A for Alzheimer's disease. Cochrane Database of Systematic Reviews 2008, John Wiley & Sons, Ltd., Chichester, UK.
18. Ligthart S.A., Moll van Charante E.P., Van Gool W.A., Richard E. Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review. Vasc. Health Risk Manag. 2010, 6:775-785.
19. Liu H., Yang M., Li G.M., Qiu Y., Zheng J., Du X., et al. The MTHFR C677T polymorphism contributes to an increased risk for vascular dementia: a meta-analysis. J. Neurol. Sci. 2010, 294(1-2):74-80.
20. Malouf R., Birks J. Donepezil for vascular cognitive impairment. Cochrane Database of Systematic Reviews 2009, John Wiley & Sons, Ltd., Chichester, UK.
21. Malouf R., Grimley Evans J. Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people. Cochrane Database of Systematic Reviews 2008, John Wiley & Sons, Ltd., Chichester, UK.
22. McGuinness B., Craig D., Bullock R., Passmore P. Statins for the prevention of dementia. Cochrane Database of Systematic Reviews 2009, John Wiley & Sons, Ltd., Chichester, UK.
23. McGuinness B., Todd S., Passmore P., Bullock R. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst. Rev. 2009, (4):CD004034.
24. McGuinness B., O'Hare J., Craig D., Bullock R., Malouf R., Passmore P. Statins for the treatment of dementia. Cochrane Database of Systematic Reviews 2010, John Wiley & Sons, Ltd., Chichester, UK.
25. McShane R., Areosa Sastre A., Minakaran N. Memantine for dementia. Cochrane Database of Systematic Reviews 2009, John Wiley & Sons, Ltd., Chichester, UK.
26. Muangpaisan W., Brayne C. Systematic review of statins for the prevention of vascular dementia or dementia. Geriatr. Gerontol. Int. 2010, 10(2):199-208.
27. Orgogozo J.M., Rigaud A.S., Stoffler A., Mobius H.J., Forette F. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 2002, 33(7):1834-1839.
28. Pendlebury S.T., Rothwell P.M. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol. 2009, 8(11):1006-1018.
29. Reynolds E.H. Benefits and risks of folic acid to the nervous system. J. Neurol. Neurosurg. Psychiatry 2002, 72(5):567-571.
30. Roman G.C. Vascular dementia revisited: diagnosis, pathogenesis, treatment, and prevention. Med. Clin. North Am. 2002, 86(3):477-499.
31. Roman G.C., Salloway S., Black S.E., Royall D.R., Decarli C., Weiner M.W., et al. Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size. Stroke 2010, 41(6):1213-1221.
32. Schrijvers E.M., Schurmann B., Koudstaal P.J., van den Bussche H., Van Duijn C.M., Hentschel F., et al. Genome-wide association study of vascular dementia. Stroke 2012, 43(2):315-319.
33. Seitz D.P., Adunuri N., Gill S.S., Gruneir A., Herrmann N., Rochon P. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst. Rev. 2011, (2):CD008191.
34. Shah K., Qureshi S.U., Johnson M., Parikh N., Schulz P.E., Kunik M.E. Does use of antihypertensive drugs affect the incidence or progression of dementia? A systematic review. Am. J. Geriatr. Pharmacother. 2009, 7(5):250-261.
35. Sharp S.I., Aarsland D., Day S., Sonnesyn H., Ballard C. Hypertension is a potential risk factor for vascular dementia: systematic review. Int. J. Geriatr. Psychiatry 2011, 26(7):661-669.
36. Sofi F., Valecchi D., Bacci D., Abbate R., Gensini G.F., Casini A., et al. Physical activity and risk of cognitive decline: a meta-analysis of prospective studies. J. Intern. Med. 2011, 269(1):107-117.
37. Wang B.S., Wang H., Wei Z.H., Song Y.Y., Zhang L., Chen H.Z. Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis. J. Neural Transm. 2009, 116(4):457-465.
38. Wang B.S., Wang H., Song Y.Y., Qi H., Rong Z.X., Zhang L., et al. Effectiveness of standardized ginkgo biloba extract on cognitive symptoms of dementia with a six-month treatment: a bivariate random effect meta-analysis. Pharmacopsychiatry 2010, 43(3):86-91.
39. Weinmann S., Roll S., Schwarzbach C., Vauth C., Willich S.N. Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatr. 2010, 10:14.
40. Wilcock G., Mobius H.J., Stoffler A. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int. Clin. Psychopharmacol. 2002, 17(6):297-305.
41. Wilkinson D., Doody R., Helme R., Taubman K., Mintzer J., Kertesz A., et al. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 2003, 61(4):479-486.
42. Williams P.S., Rands G., Orrel M., Spector A. Aspirin for vascular dementia. Cochrane Database Syst. Rev. 2008, (4):CD001296.
43. Zhou B., Xu Z., Kuang Y., Deng Y., Liu Z. Effectiveness of polydrug therapy for senile dementia. Chin. J. Clin. Rehabil. 2004, 8(7):1214-1215.